Aim for drug free remission in early RA? After 1 yr remission Pts randomized to stop Rx vs 1/2 dose. More flares if no Rx. For 1/2 dose if 2 yrs remission randomize to stop or stay at 1/2 dose. 2X more flares if d/c Rx. Abst2013 Arctic rewind #ACR22 @rheumnow #ACRBest Relevant ? https://t.co/nfQPExhbYj

Once again, high BMI and smoking associated with substantial decrease in TNFi response for treatment of axSpA. Easier said than done however. How are you helping pts lose weight or stop smoking? Abs#1510 @RheumNow #ACR22 https://t.co/ircLkuXhCs

Fulvio et al. Labial gland US to identify lymphoma in Sjogrens. OMERACT score of 3 in 100% of lymphoma and 35% non-lymphoma @RheumNow #ACR22 Abstr#1254 https://t.co/aspctOfGp8 https://t.co/CLhN2PTvaS

Gut microbiota of axSpA pts who underwent bDMARD tx for one year more closely resembled controls. Unique enrichment of Collinsella in axSpA patients remained stable across time & tx, suggesting it may be a disease biomarker. Abs 1162 #ACR22 @RheumNow https://t.co/SjwORWp6IU https://t.co/rLlu4jGCfd

How many rheumatologists are managing psoriasis themselves? Or dermatologists managing arthritis themselves? Survey shows <50% rheum collaborate with derm Need updated EMRs and additional education Abs#1502 @RheumNow #ACR22 https://t.co/1okhxFAbUS

Plenary: Real-world observational study >1500 pts with IA, 1 year retention infliximab biosimilar CT-P13 to GP1111 switch was high. Retention was higher in originator-experienced (92vs83%) & low disease activity Nabi H, DANBIO Abs1112 https://t.co/z84AMUS3GK #ACR22 @RheumNow https://t.co/SgGhd33Esl

Plenary: Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s ◦ Favourable safety profile ◦ Well-tolerated over 24 Wks ◦ Improved ESSDAI, salivary flow, Igs ◦ May be first effective oral disease-modifying therapy for SS Dorner T Abs1113 https://t.co/FkgJpwKAJL #ACR22 @RheumNow https://t.co/znxMc27EBI

Frailty in Vasculitis Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at #ACR22 Convergence. https://t.co/aMpcBhT5yE https://t.co/rPgA19dT0W

Does MTX dose matter for COVID mRNA vaccine immunogenicity in RA pts? Single-center (n=126) with one MTX dose WH post-each vaccine Similar humoral response Big error bars suggest other factors more important ABST0913 #ACR22 @RheumNow (not pretty graphs but data interesting!) https://t.co/FFfTWiNjUY

Henry @EBRheum et al. Less than 1 in 6 recommendations from ACR/EULAR informed by comparative effectiveness RCT. Many receive strong recommendation despite low/very low LOE. @RheumNow #ACR22 Abstr#1284 https://t.co/1MUM8qiwDl https://t.co/KJcf7rBQAU